Rezolute Inc. (RZLT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Rezolute Inc. (RZLT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.69

-0.06 (-1.26%)

At close: Jan 14, 2025, 3:59 PM

4.72

0.64%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	4.58
Market Cap	271.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.27
PE Ratio (ttm)	-3.69
Forward PE	n/a
Analyst	Buy

Ask	4.94
Volume	388,601
Avg. Volume (20D)	403,501
Open	4.83
Previous Close	4.75
Day's Range	4.69 - 4.98
52-Week Range	0.90 - 6.19
Beta	undefined

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 14, 2013

Employees 59

Stock Exchange NASDAQ

Ticker Symbol RZLT

Website https://www.rezolutebio.com

Analyst Forecast

According to 8 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 145.20% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 months ago · Source

+22.07%

Rezolute shares are trading higher after the compa... Unlock content with Pro Subscription

7 months ago · Source

-23.45%

Rezolute shares are trading lower after the company announced a proposed public offering of common stock and pre-funded warrants.

News

1 week ago · zacks.com

Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT)

If you are looking for stocks that are well positioned to maintain their recent uptrend, Rezolute (RZLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price ...

3 weeks ago · zacks.com

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

1 month ago · zacks.com

RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug

The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise.

1 month ago · seekingalpha.com

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congeni...